Trial Profile

A Phase 2 study of Antroquinonol as the first-line treatment of Acute Myeloid Leukemia (AML)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antroquinonol (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

07 Dec 2020 New trial record
26 Nov 2020 According to a Golden Biotechnology Corporation media release, the company plans to apply the clinical trial (IND) for Antroquinonol (HOCENA) to the U.S. FDA for the Phase 2 clinical trials as the first-line treatment of AML.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com